Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1094-1104

  Wang, Ying Hong ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CLARITHROMYCIN; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DILTIAZEM; ERYTHROMYCIN; FLUOXETINE; MIDAZOLAM; NIFEDIPINE; RITONAVIR; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; TRIAZOLAM; VERAPAMIL; ZOLPIDEM; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL OBSERVATION; COMPARATIVE STUDY; DRUG ABSORPTION; ENZYME DEGRADATION; ENZYME SUBSTRATE; IN VITRO STUDY; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; SIMCYP TIME BASED APPROACH; STATIC MATHEMATICAL MODEL; COMPUTER SIMULATION; DRUG INTERACTION; EVALUATION STUDY; FORECASTING; HUMAN; PHARMACOKINETICS; PROCEDURES; THEORETICAL MODEL;

COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; FORECASTING; HUMANS; MODELS, THEORETICAL; PHARMACOKINETICS;

EID: 77953787344     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032177     Document Type: Article

References (59)

1. Allard S, Sainati S, Roth-Schechter B, and MacIntyre J (1998) Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 26:617-622. (Pubitemid 28345844)
2. Backman JT, Olkkola KT, Aranko K, Himberg JJ, and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225. (Pubitemid 24212179)
3. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, and Affrime MB (1995) Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 58:269-278.
4. Chu S, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, and Cavanaugh JH (1993) Single-and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 33:719-726. (Pubitemid 23260398)
5. Chu SY, Deaton R, and Cavanaugh J (1992) Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 36:1147-1150.
6. Dilger K, Eckhardt K, Hofmann U, Kucher K, Mikus G, and Eichelbaum M (1999) Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol 47:413-419.
7. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
8. Ernest CS 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
9. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
10. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
11. Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, and Greenblatt DJ (2009) Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 85:644-650.
12. Fenneteau F, Poulin P, and Nekka F (2010) Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 99:486-514.
13. Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW, and Cavanaugh JH (1990) Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 18:441-446.
14. Food and Drug Administration (2006) FDA Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implication for Dosing and Labeling, US Department of Health and Human Services; Rockville, MD.
15. Gascon MP and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
16. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, and Harmatz JS (1992) Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52:479-486.
17. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, and Shader RI (1998) Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 64:278-285.
18. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000a) Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 67:335-341.
19. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000b) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136.
20. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, and Cheboyina S (2006) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46:201-213.
21. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, and Tong Y (2008) Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 83:61-69.
22. Hedaya MA, El-Afify DR, and El-Maghraby GM (2006) The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharm Drug Dispos 27:103-110.
23. Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140-1146.
24. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
25. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426.
26. Kantola T, Kivistö KT, and Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177-182.
27. Kosuge K, Nishimoto M, Kimura M, Umemura K, Nakashima M, and Ohashi K (1997) Enhanced effect of triazolam with diltiazem. Br J Clin Pharmacol 43:367-372.
28. Lam YW, Alfaro CL, Ereshefsky L, and Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274-1282.
29. Lefebvre M, Lacasse Y, Spénard J, Geadah D, Moisan R, Gossard D, Landriault H, Du Souich P, and Caillé G (1994) Pharmacokinetics and pharmacodynamics of a slow-release formulation of diltiazem after the administration of a single and repeated doses to healthy volunteers. Biopharm Drug Dispos 15:227-242.
30. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
31. Mousa O, Brater DC, Sunblad KJ, and Hall SD (2000) The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 67:267-274.
32. Muirhead GJ, Faulkner S, Harness JA, and Taubel J (2002) The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 53 (Suppl 1):37S-43S.
33. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, and Buss N (2000) Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 50:99-107.
34. Ochs HR and Knüchel M (1984) Pharmacokinetics and absolute bioavailability of diltiazem in humans. Klin Wochenschr 62:303-306.
35. Ohashi K, Sudo T, Sakamoto K, Tateishi T, Fujimura A, Kumagai Y, and Ebihara A (1993) The influence of pretreatment periods with diltiazem on nifedipine kinetics. J Clin Pharmacol 33:222-225. (Pubitemid 23129499)
36. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, and Ohashi K (2007) Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 47:871-876.
37. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305. (Pubitemid 23094372)
38. Palkama VJ, Ahonen J, Neuvonen PJ, and Olkkola KT (1999) Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 66:33-39.
39. Piergies AA, Sweet J, Johnson M, Roth-Schechter BF, and Allard S (1996) The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 34:178-183. (Pubitemid 26109238)
40. Robbins-Weilert DK, Giesing DH, and Weir SJ (1999) Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers. Am J Ther 6:211-216.
41. Suwa T, Yoshida H, Kohno Y, Yoshitumi S, and Ohta K (1988) Metabolic fate of TE-031 (A-56268). III. Absorption, distribution and excretion of 14C-TE-0341 in rats, mice and dogs. Chemotherapy 36:213-226.
42. Tateishi T, Ohashi K, Sudo T, Sakamoto K, Toyosaki N, Hosoda S, Toyo-oka T, Kumagai Y, Sugimoto K, and Fujimura A (1989) Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol 29:994-997. (Pubitemid 20038078)
43. Turner DB, Rostami-Hodjegan A, Tucker GT, and Rowland-Yeo K (2006) Prediction of nonspecific hepatic microsomal binding from readily available physiochemical properties. Proceedings of the 9th European ISSX Meeting; 2006 Jun 4-7; Manchester, UK. International Society for the Study of Xenobiotics, Washington, DC.
44. Varhe A, Olkkola KT, and Neuvonen PJ (1996) Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 59:369-375.
45. Wang YH, Gorski JC, Hamman MA, and Hall SD (2004a) Age and sex effects on the recovery of CYP3A inhibition by clarithromycin. Drug Metab Rev 36 (Suppl 1):287.
46. Wang YH, Jin Y, Ho H, Hilligoss JK, Hu Z, Gorski JC, and Hall SD (2005) Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil (Abstract). Clin Pharmacol Ther 77:P3.
47. Wang YH, Jones DR, and Hall SD (2004b) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
48. Wright CE, Lasher-Sisson TA, Steenwyk RC, and Swanson CN (1992) A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 12:103-106.
49. Xu L, Chen Y, Pan Y, Skiles GL, and Shou M (2009) Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330-2339.
50. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 29:443-452.
51. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2005) Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334-340.
52. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
53. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
54. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, and Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514-519.
55. Yeates RA, Laufen H, and Zimmermann T (1996) Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 34:400-405. (Pubitemid 26305815)
56. Yeo KR and Yeo WW (2001) Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51:461-470.
57. Zhang X, Quinney SK, Gorski JC, Jones DR, and Hall SD (2009) Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 37:1587-1597.
58. Zhao P, Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861.
59. Zhao P, Lee CA, and Kunze KL (2007) Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 35:704-712.